Senzime confirms final negotiations of a licensing agreement with a global market leader
Press release: Uppsala, May 19, 2022. Senzime today announces that the company is in final negotiations regarding a strategic licensing and development agreement with a market leading global player in patient monitoring.
The agreement is expected to be signed during the current quarter, enabling Senzime’s technology platform for monitoring depth of neuromuscular blockade to integrate with the counterparty’s system.
One of Senzime’s business focuses is to develop strategic partnerships to integrate and accelerate the penetration of the company’s technology through product collaborations.
Pia Renaudin, CEO at Senzime, says: "Senzime's TetraGraph system is well established globally. An increasing number of guidelines, both nationally and at hospital level, are driving the use of objective neuromuscular monitoring. This means that the addressable market is growing faster. The industrial interest in our solutions and the possibility of connecting TetraGraph to central monitoring systems increases. We are now in the final negotiation of what is our most important licensing agreement and partnership to date, which enables the integration of TetraGraph in thousands of already installed patient monitoring systems.”
Senzime has delivered more than 1,200 TetraGraph systems. 2022 began with the reporting of ongoing or contracted trials at 74 hospitals which by the end of the first quarter had resulted in 27 won and 0 lost deals as well as 29 new trials.
Senzime is a Swedish medical device company that develops and markets CE- and FDA-cleared monitoring systems for patients undergoing anesthesia. Senzime’s employees worldwide are committed to the vision of a world without anesthesia related complications. Six out of ten patients that wake up after surgery are not fully muscle recovered and therefor at risk having critical respiratory complications. The TetraGraph system helps anesthesia providers improve patient care and reduce healthcare costs by digitally and continuously measure the degree of neuromuscular blockade under and after surgery. Senzime operates in the worlds leading markets targeting a market opportunity valued in excess of SEK 15 billion per year. The company’s shares are listed on Nasdaq Stockholms main market (ticker SEZI). www.senzime.com
This information is information that Senzime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-05-19 15:15 CEST.